IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

Marc Humbert(Inserm), Nikolaos G. Papadopoulos(National and Kapodistrian University of Athens), Óscar Palomares(Universidad Complutense de Madrid), Claus Bachert(University Hospital Münster), Simon Francis Thomsen(University of Copenhagen), Jean Bousquet(Charité - Universitätsmedizin Berlin), Ioannis Kottakis(Novartis (Switzerland)), Xavier Jaumont(Novartis (Switzerland)), Pascal Pfister(Novartis (Switzerland))
The Journal of Allergy and Clinical Immunology In Practice
March 27, 2019
10.1016/j.jaip.2019.02.030
Cited by 111

Related Papers

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy
|Allergy|2014|1.4k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study
|Allergy|2011|1.1k
EAACI Molecular Allergology User's Guide
|Pediatric Allergy and Immunology|2016|909